MORPHEUS Model Areas for Removal of Pharmaceutical Substances in the South Baltic

Transcription

1 MORPHEUS Model Areas for Removal of Pharmaceutical Substances in the South Baltic Planned date of project start Planned date of project completion Valdas Langas Klaipeda University EUSBSR PA Hazards seminar in Vilnius,

2 Project Area Kristianstad Klaipeda South Baltic Sea Gdansk Rostock

3 MORPHEUS Project Partners SWEDEN 1. Kristianstad University, Lead Partner (WP1, Management and coordination) GERMANY 2. The Coastal Union, EUCC (WP2, Communication and dissemination) 3. University of Rostock (WP3, Regional Consumption Patterns of Pharmaceuticals) POLAND 4. Gdansk Water Foundation (WP6, Training and education programme) 5. Gdansk University of Technology (WP5, Possibilities of Implementation of Advanced Treatment Technologies) LITHUANIA 6. Environmental Protection Agency (represented by Marine Research Department) 7. Klaipeda University (WP4 - Estimating the Regional Pharmaceutical Burden in Selected WWTPs and Water Bodies)

4 MORPHEUS Associated Partners SWEDEN 1 Region of Skåne 2 The municipality of Kristianstad GERMANY 3 Leibniz Institute for Baltic Sea Research Warnemünde (IOW) 4 State Agency of Environment, Nature Conservation and Geology Mecklenburg- Vorpommern 5 EURAWASSER North GmbH // Warnow Water and Wastewater Association POLAND 6 WWTP EKOWIK Ltd (municipal water company) 7 WWTP PEWIK Ltd LITHUANIA 8 Joint-stock company Klaipėdos Vanduo 9 Limited liability water company "Palangos vandenys"

5 MORPHEUS-list of substances EU DECISION 2015/495 Name of substance/group of substances Medžiagos arba medžiagų grupės pavadinimas 1 17-Alpha-ethinylestradiol (EE2) 17-alfa-etinilestradiolis (EE2) 2 17-Beta-estradiol (E2), Estrone (E1) 17-beta-estradiolis (E2), estronas (E1) 3 Diclofenac Diklofenakas 4 2,6-Ditert-butyl-4-methylphenol 2,6-di-tret-butil-4-metilfenolis 5 2-Ethylhexyl 4-methoxycinnamate 2-etilheksil-4-metoksicinamatas 6 Macrolide antibiotics Makrolidų grupės antibiotikai 7 Methiocarb Metiokarbas 8 Neonicotinoids Neonikotinoidai 9 Oxadiazon Oksadiazonas 10 Tri-allate Trialatas CAS number CAS Nr , , Maximum acceptable method detection limit (ng/l) Didžiausia priimtina metodo aptikimo riba (ng/l) 0,

6 MORPHEUS Objectives Project objective To provide knowledge on advanced treatment technologies and the estimated environmental burden caused by consumption of pharmaceuticals in four coastal areas to WWTP operators and regional decision-makers Programme specific objective Increased use of green technologies in order to decrease the pollution discharge in the South Baltic Area Project results Increased ability of WWTP operators and regional decision-makers to take informed decisions when investing into suitable advanced treatment technologies in order to reduce the pharmaceutical burden on coastal waters in the future Programme expected result Increased used of green technologies by South Baltic area stakeholders benefiting from cross-border cooperation

7 MORPHEUS Work Package 2 Communication and dissemination Target groups for information about project activities and outcomes: Local stakeholders/end-users from municipalities, environmental agencies, wastewater treatment plants; regional, national, international political decision-makers; project partners, associated partners, consumers, general public, Approach: General information tools (e.g. homepage, leaflets, brochures, social media), disseminating road maps Participation in scientific and cross-border events

8 MORPHEUS Work Package 3 Regional Consumption Patterns of Pharmaceuticals to gather consumption data to the highest spatial and temporal resolution available a possible relation between consumption/emission and environmental chemical burden in receiving waters in the SBS will be investigated. Key deliverables will be a report on pharmaceutical consumption/emission patterns in four coastal regions Using Mass Flow Analysis tools, the data will be used to estimate in- and outflow loads of specific WWTP s in the regions. Deliverables: Report on pharmaceutical consumption patterns in four coastal regions (mapping, analysis the consumption, estimating in- and outflow loads of WWTP). The report will summarise information on pharmaceutical consumption based on prescription of pharmaceuticals in the four model areas and give an overview of consumption patterns.

9 MORPHEUS Work Package 4 Estimating the Regional Pharmaceutical Burden in Selected WWTPs and Water Bodies WP4 is assessing the actual end-of-the-pipe emissions in selected WWTPs and the related chemical burden in ambient water systems (sampling and analysis, interpretation of data on chemicals behaviour and fate). basic training in organic trace chemical analysis for partners and associated organizations in parallel to the analysis of samples from the partner regions. Deliverables: Report on pharmaceutical chemical burden in four coastal regions (SE, DE, PL, LT) sampling campaign-protocols collection analysis at Kristianstad University Hands-on training in chemical analysis for partners and associated organisations Data evaluation and interpretation recommendations. Report on relation between pharmaceutical consumption, environmental pharmaceutical burdens and current treatment technologies. Hands-on training in chemical analysis for Project Partners and Associate Partners.

10 Kristianstad Helge Å river basin 4750 km 2 Klaipeda Akmena-Dane river basin 579 km 2 Rostock Warnow river basin 3324 km 2 Gdansk Martwa Wisla River river basin km 2

11 MORPHEUS project monitoring points in Lithuania Urban areas Klaipėda Palanga Population in 2015 ~ Population (tourists in summer time) ~ (tourists in summer time) Sampling stations (points) No of samples WWTP (winter, summer) in/out 4 Klaipeda Strait near the outlet Klaipėda Strait, upstream WWTP (winter, summer) in/out 4 Treated wastewater receiver the Baltic Sea Open Sea (background area) Kretinga Nida (municipality) (tourists in summer time) WWTP (summer, winter) in/out 4 Treated wastewater receiver river Tenžė 2 Akmena-Dane river mouth (winter, summer) WWTP (summer, winter) in/out 4 Treated wastewater receiver Curonian lagoon (winter, summer): near the outlet Curonina Lagoon (background area) 2 Total: 32 (WWTP 16; Water bodies 16)

12 MORPHEUS Work Package 5 Possibilities of Implementation of Advanced Treatment Technologies Based on the information made available in WP 3, 4 and 5 a basic understanding of the need of treatment of pharmaceuticals at certain selected sites in the regions will be outlined. Deliverables: Inventory of existing treatment technologies in WWTP in partner regions. Overview of advanced treatment technologies. WP5 includes identifying, and compiling an inventory of the main WWTPs in partner regions (questionnaires, site visits with advanced treatment of micropollutants, cost-benefit assessment, creating roadmaps with recommendations for investments for at least four WWTPs/model-sites located in the regions).

13 MORPHEUS Work Package 6 Training and education programme WWTPs operators are not very familiar with advanced treatment technologies. The aim of WP 6 is to prepare a scheme and conduct trainings for WWTP operators/technology designers/controlling bodies, etc. suitable for removal of micropollutants and professional staff at chemical laboratories. (investigation of training need, creating training course syllabus with incorporated key results from WP3, 4, 5). Deliverables: Training material for target groups, short educational leaflets, conducting trainings with target groups in partner regions.

14 MORPHEUS main outputs Guidance document on the need of removal of pharmaceuticals from wastewater in the coastal regions of the SBS (Joint output of WP 3 and WP 4). Roadmaps for uptake of advanced treatment for at least four model site WWTPs located in the SB coastal areas. Training course on chemical analysis and advanced treatment technologies for target group.

15 Added value of participation in projects funded by INTERREG and other transnational funding programmes Additional funding and motivation for employees of participating organizations New knowledge and data on pharmaceuticals consumption, emissions and concentrations New knowledge and application possibilities on advanced WWT technologies and lab analysis Will serve as model areas to other areas or region Interaction between decision makers and science Cooperation and experience exchange with other countries